Aims: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solution (TIS) using the I-neb device to the standard PARI-LC Plus nebulizer in children with cystic fibrosis.
Pa lung infection. 3 However, TIS administration with the recommended PARI-LC Plus nebulizer (PARI GmbH, Starnberg, Germany) is time-consuming and requires the use of a noisy and large compressor, for which the presence of an external power source is required.
Therefore, treatment compliance and quality of inhalation are often low 4 and this may impair the beneficial effects of therapy. Moreover, standard nebulizer therapy is very inefficient. A lung deposition of only 5-15% of the initial dose can be achieved and the administered lung dose is highly variable and dependent upon the patient's breathing pattern. 5, 6 More convenient alternatives have been introduced in recent years, such as tobramycin inhalation powder and mesh or smart nebulizers. The I-neb (Philips Respironics, Chichester, UK) is a small, silent and battery-powered mesh nebulizer that uses adaptive aerosol delivery for a reproducible dosimetric output during inspiration. 7 A lung deposition of 45-75% of the initial dose can be reached, in a shorter nebulization time compared to conventional nebulization. [8] [9] [10] [11] Usage of the I-neb can reduce treatment burden and this nebulizer is already widely used in adults and increasingly in children. [12] [13] [14] [15] However, the I-neb has not been tested in children and little is known about pharmacokinetics (PK) and safety of tobramycin delivered with this nebulizer. This lack of knowledge is especially a risk with drugs such as tobramycin, where high trough concentrations and cumulative exposure can lead to nephro-and ototoxicity. 16, 17 Dose recommendations are based on in vitro tests and few in vivo data in adults. 9, 18 The I-neb is registered for use with inhaled colistin in the UK, but is increasingly used to deliver TIS off-label in children. Therefore, it is important to investigate whether the recommended dose for tobramycin inhalation using the I-neb is correct in children and if this combination can be used safely in routine paediatric CF care. While the intent of this study is not to recommend that patients use the I-neb as an off-label device to inhale TIS, the authors felt an obligation to generate these data to ensure that the expansion of this practice in the real-world setting is safe for children using TIS. We hypothesized that recommended doses using the I-neb for TIS inhalation might be too high for the younger children, which may give rise to a risk for toxicity. Therefore, we designed a study in children with CF aged 6-18 years with the primary aim to compare PK and systemic exposure of TIS inhalation between the I-neb and PARI-LC Plus nebulizer including an age subanalysis. As secondary aims we assessed patient satisfaction and short-term safety at 1 month using standard testing and more sensitive biomarkers for aminoglycoside toxicity.
2 | METHODS
| Study population
The study was performed at 3 specialized CF centres in The What is already known about this subject
• Tobramycin inhalation solution (TIS) administration with the recommended PARI-LC Plus nebulizer is effective for treatment of Pseudomonas aeruginosa infection in children with cystic fibrosis (CF).
• Usage of the I-neb can reduce treatment burden, because this nebulizer is considerably faster, more efficient and more convenient to use.
• The correct dose and safety of TIS inhalation with the I-neb should be investigated before using this off-label combination in routine paediatric CF care.
What this study adds
• Nebulization of 75 mg TIS with the I-neb in children with CF resulted in comparable systemic exposure and safety to 300 mg TIS with the PARI-LC Plus.
• Nebulization time was significantly shortened with the I-neb and the nebulizer was well tolerated and preferred over the PARI-LC Plus.
• During the visits blood, urine, and sputum or throat swab samples were collected, spirometry and hearing tests were performed and questionnaires were filled out by the children or their parents. Degree of symptoms regarding cough, sputum production, exercise tolerance, fatigue and disturbed sleep was also scored. Test protocols were equalized as much as possible for the 3 participating CF centres regarding equipment and analysis.
Compliance was determined by counting the number of returned TIS ampoules.
| Protocol amendment
Following inclusion of patient 14, a protocol amendment was written.
The investigators noticed that newer nebulizers, such as the I-neb, were increasingly prescribed and preferred by patients, and that the standard nebulizer PARI-LC Plus was less used in daily practice. As patients did not want to run the risk to be assigned to the PARI-LC Plus treatment arm, inclusion rate decreased. From inclusion number 15 onwards patients were assigned to the I-neb during the 28-days treatment period at home. As a consequence, more safety data were collected for the I-neb and relatively fewer for the PARI-LC Plus. Since patients still performed a supervised inhalation with both nebulizers, the primary endpoint of the study did not change. 
| PK
For tobramycin monitoring, dried blood spots using a finger prick were collected before (t = 0) and 15, 45 and 90 minutes after completion of the supervised inhalation. Samples were collected by patients themselves at home 3, 6 and 24 hours after inhalation. 20 Careful instruction was given to clean hands and fingers before blood was taken.
Tobramycin was measured in the dried blood spots using a validated liquid chromatography-tandem mass spectrometry method and individual PK parameters were calculated and assimilated with patient tobramycin serum concentrations using Bayesian modelling software /Dose (I-neb) ).
| Age dependency, safety and patient satisfaction
Secondary endpoints included: differences in AUC 0-24h between age groups 6-11 and 12-18 years (pharmacokinetics); trough concentrations, change in renal and hearing function after 1 month inhalation and change in forced expiratory volume in the first second (FEV 1 ) before and after supervised inhalations (safety); quality of life, adverse events, tolerability, nebulization time and nebulizer satisfaction (patient satisfaction). For an extensive method description about the secondary endpoints, see Appendix S1.
| Renal toxicity
Estimated glomerular filtration rate based on serum creatinine (eGFR)
is the standard clinical measure to assess and monitor renal function.
However, the eGFR is considered to be an insensitive marker for acute kidney injury (AKI), because changes in serum creatinine are delayed in time and at least 25-50% of the functional nephron capacity has to be lost before this parameter decreases significantly. 21 Furthermore, serum creatinine is a marker for glomerular fil- 3 | RESULTS
| Study population
Twenty-two children with CF with a median age of 11 years were included in the study: 6 patients in The Hague, 5 in Rotterdam and 11 in Utrecht. All patients completed PK data collection for both nebulizers. For the home treatment period, 6 patients used the PARI-LC Plus and 16 patients the I-neb nebulizer. Table 1 reports patient characteristics baseline values (visit 1). There were no significant differences in renal or lung function between study visits.
Patient characteristics were comparable for the 2 treatment arms.
Patients also had similar degree of symptoms regarding cough, sputum production, exercise tolerance, fatigue and disturbed sleep at visits 1 and 2. Compliance rate was comparable between treatment arms with a median value of 96% (range 55-100%).
Safety data from patients 4 and 8 regarding renal and ototoxicity could not be evaluated, since both patients were unable to complete 
| Pharmacokinetics
Serum concentration-time profiles are shown in Figure 1 (see Supplementary Table S1 for details). All tobramycin serum concentrations were 0 mg/L predose at both visits. No significant differences were found between I-neb and PARI-LC Plus TIS nebulization in the administered doses and treatments were considered to be bioequivalent (see Table 2 ). Mean AUC 0-24h ,C max , C trough12h , C trough24h and T max 
| Age dependency and correlations
There were also no significant differences between nebulizers for each age group, except for a higher T max for the I-neb in patients 6-11 years (P = .043, see Figure 2 ). Differences in PK parameters between the 2 age groups were not statistically significant, except for T max for the PARI-LC Plus whereby older patients reached C max significantly later compared to the younger ones (P = .041, see Figure 2 ).
No significant interaction effects between study visit day and nebulizer or between age group and nebulizer were found. Regression analysis revealed no correlations between PK parameters and the child's age, weight, FEV 1 or eGFR values.
| Safety and patient satisfaction
Results of audiometry and eGFR revealed no abnormalities. Increased urinary NAG/creatinine ratios at visit 2 for both nebulizers suggest, however, that TIS-induced subclinical tubular kidney injury (see Table 3 ). Nebulization time was 50% shorter and patient satisfaction significantly higher with the I-neb (see Table 4 ). For full results of the secondary endpoints, see Appendix S2. Differences between treatment arms were not significant. 
| PK
The primary endpoint was systemic bioavailability of inhaled tobramycin, defined as serum tobramycin AUC 0-24h . No significant difference between nebulizers for this endpoint was found, nor for other PK parameters, and serum concentrations were in accordance with previously reported values. [22] [23] [24] [25] The results were found to be independent from age, weight and lung function of the child. Median F rel (bioavailability of TIS with the I-neb relative to the PARI-LC Plus) FIGURE 2 Time to maximum serum concentration (T max ) following tobramycin inhalation solution nebulization, reported per age group. In patients 6-11 years: T max was significantly higher for the I-neb compared to the PARI-LC Plus (P = .043); no difference between nebulizers for age group 12-18 years (P = .764). When comparing age groups: older patients had a significantly higher T max compared to younger patients for the PARI-LC Plus nebulizer only (P = .041) Data are presented as median (range). Differences between nebulizers were not significant. AKI = acute kidney injury; KIM-1 = kidney injury molecule-1; NAG = N-acetyl-β-D-glucosaminidase; eGFR = estimated glomerular filtration rate (Schwartz formula).
a For patients with biomarker values below the lower limit of quantitation, a value 50% of this limit was used to calculate the ratio. Subgroup analysis revealed no differences in PK parameters between age groups except for T max , for which possible explanations can be appointed. Since subgroups were small and variability was large, clinical relevance of this finding is however uncertain and no firm conclusions can be drawn. First, in patients aged 6-11 years a higher T max was found for the I-neb compared to the PARI-LC Plus.
This difference can be explained by a longer nebulization time for the PARI-LC Plus (approximately 19 vs 13 minutes for the I-neb).
Because sample collection started immediately after completion of the inhalation, sampling started earlier in the I-neb group leading to a mean difference of 6 minutes in time from start of nebulization.
From the beginning of nebulization there is absorption and clearance and when 6 minutes is subtracted from the mean T max , there is no significant difference. Secondly, it was found that older children (age 12-18 years) reached C max significantly later compared to the younger ones when inhaling with the PARI-LC Plus. A possible explanation could be delayed absorption due to increased mucus plugging in older children. Children in the older age group using the PARI-LC Plus nebulizer had significantly lower FEV 1 values compared to the younger children using this nebulizer (median 68.8 vs 99.7% predicted, respectively). Furthermore, there were no differences in lung function between the 2 age groups for inhalation with the I-neb, which might explain similar T max for this nebulizer.
Variability in systemic exposure of inhaled antibiotics is known to be large in CF patients and was also considerable in our study.
Heterogeneity in disease severity and renal function, but also age, weight and variable competence in inhalation technique of the child may contribute to this variability. However, no correlations between PK parameters and the child's age, weight, FEV 1 or eGFR values were found. Interestingly, similar coefficients of variation were calculated for the nebulizers. Because of the adaptive aerosol delivery system, a lower variability was expected with I-neb nebulization as was recently shown for another controlled-inhalation device in adults. 
| Safety
The secondary aim was to assess short-term safety of 1 month of TIS.
Tobramycin serum concentrations are often used as proxy for safety since high trough concentrations and cumulative exposure are related to the development of nephro-and ototoxicity. However, no clear toxic limits have been defined yet for tobramycin during chronic inhalation. Based on intravenous administration, a trough concentration below 1 mg/L is considered to be safe. 26 Calculated trough serum concentrations 12 hours after completion of the supervised inhalation were below toxic limits for all patients, suggesting that twice daily TIS nebulization is safe with both nebulizers.
Because of the protocol amendment most patients were assigned to the I-neb treatment (n = 14) and only few patients of the PARI-LC Plus treatment arm could be included in the audiometry analysis (n = 4) and AKI biomarker (n = 3), respectively. Consequently, reliable comparison between nebulizers regarding safety could not be made, though results seemed to be similar.
Aminoglycosides have a cochleotoxic effect and can cause irreversible hearing loss. Audiometry results showed no abnormalities for most patients, which is in accordance with results from other studies regarding TIS safety. 16, 27 Tobramycin is also known to damage the kidneys with toxic effects mainly targeted to the proximal tubule Data are presented as mean ± standard deviation. studies, variability was large and differences in nebulizer and dosing regimens hampers comparison between studies.
Interestingly, no significant differences in KIM-1/creatinine ratios between study visits were found in our study, while a recent review suggests that KIM-1 outperforms other biomarkers in preclinical and clinical studies of aminoglycoside-induced nephrotoxicity. 31 Those patients may be even more at risk for TIS-induced renal toxicity, since there is no recovery time in an off-period.
| Patient satisfaction
Patients were more satisfied with the I-neb nebulizer. At home, patients had a 2 times shorter nebulization time with the I-neb compared to the PARI-LC Plus. However, nebulization time for the I-neb measured at the study visit was longer than the reported time at home, while no such difference was found for the PARI-LC Plus.
Possibly, more time was spent at the study visit for correct use of the I-neb, especially for I-neb naïve patients. Combined with an expected learning curve in the home treatment period, this could explain the higher nebulization time during the study visit.
| Limitations
There are several limitations to address. There is a wide degree of variation in our PK results, although this degree of variability is not unusual for inhaled drugs and is inherent to the individual inhalation technique. Furthermore, the study was not powered for the secondary aim: the safety data. Therefore, safety data were obtained in a relatively small number of patients and gathered over a period of 28 days with no follow-up. Also, because of the lack of serum sampling at day 28, possible accumulation following a regular treatment period could not be assessed. Therefore, only statements can be made about short-term safety and further research is necessary to assess longterm safety and reversibility of (subclinical) toxic effects in a larger group of patients.
Moreover, only systemic exposure and no tobramycin airway concentrations or direct lung deposition were measured and clinical efficacy outcomes were not assessed in this study. However, TIS nebulization with the PARI-LC Plus is an effective and approved treatment option for CF patients with Pa infection. 3 It is also known that serum PK can be used well as surrogate for total lung deposition 10, 22, [37] [38] [39] and that it is a better measure compared to sputum drug concentrations, which mainly reflects deposition in the large airways. Therefore, for device comparison purposes, one can translate the obtained bioequivalence with the I-neb (75 mg) compared to the PARI-LC Plus (300 mg) in this study, into an expected equivalent deposition and efficacy. We did perform Pa culture in sputum or throat swab samples in order to assess the success rate for eradication patients. The success rate was 100% for the PARI-LC Plus users (2 out of 2) and 75% for the patients using the I-neb (6 out of 8). This is comparable to the ELITE study where a success rate of 66% was reached with 28 days of TIS nebulization with the PARI-LC Plus. 40 Reliable comparison between nebulizers could not be made because of the small numbers (unpowered) and skewed randomization.
| CONCLUSION
In conclusion, this study has shown that nebulization of 75 mg TIS with the I-neb in children with CF resulted in similar systemic exposure to 300 mg TIS with the PARI-LC Plus with no clear clinical signs of toxicity after 1 month of inhalation. Therefore, our results suggest that the I-neb nebulizer in combination with 75 mg TIS can be used safely in routine paediatric CF care. No age-or weight-dependent tobramycin serum concentrations were found, hence age-or weightbased dosage adjustments are not necessary. Nebulization time was significantly shortened and a higher degree of satisfaction was attained with the I-neb nebulizer, which may improve the level of adherence and treatment outcomes. 41 Although long-term, intermittent TIS nebulization is considered to be safe and well tolerated, 42, 43 raised urinary NAG/creatinine ratios with the absence of decreased eGFR in the present study suggest TIS-induced subclinical tubular kidney injury. Therefore, this study stresses the need for carefully monitoring for toxic effects of aminoglycosides in patients on chronic TIS therapy, especially when new nebulizers are used. Also, in future TIS safety studies, the predictive value of novel AKI biomarkers such as NAG and KIM-1 must be assessed, as well as their clinical relevance for CF patients using TIS or other aminoglycosides and especially for those on continuous inhalation regimens.
